



European Monitoring Centre  
for Drugs and Drug Addiction

PROGRAMME

# Annual expert meeting on Drug-related deaths (DRD) and Drug-related infectious diseases (DRID)

15–17 October 2014  
**EMCDDA, Lisbon**

## Annual expert meeting on Drug-related deaths (DRD) and Drug-related infectious diseases (DRID)

More information and updates will be available on <http://www.emcdda.europa.eu/expert-meetings/2014/drd-drid>

### Day 1 – Wednesday, 15 October 2014

Conference Centre

#### DRD Key indicator

09.00

#### Session 1: Introduction to the meeting, most recent national data and a focus on Nordic countries

Chair: Julián Vicente, EMCDDA

Discussion of most recent key indicator and national developments: Fonte reports 2014 — Isabelle Giraudon, EMCDDA

On-going increase of overdose deaths: contribution of polydrug use — Anna Fugelstad, Sweden

Opioid dependence and treatment for the 21st century: Norwegian national overdose prevention strategy — Thomas Clausen, Norway

Brief communications: on-going projects and late braking concerns:

- Pregabalin and gabapentin in opioid overdose deaths — Ilkka Ojanperä, Finland
- EU-MADNESS project on NPS: objectives and expected outcomes, with a special focus on methodologies in respect of NPS-related deaths — John Corkery, United Kingdom
- Povidone/Marindale methadone case — Thomas Clausen, Norway

10.30

Coffee break

11.00

#### Session 2: Parallel sessions A and B

Room CdS 107

Conference Centre

#### Implications of benzodiazepine in drug-related deaths (2A)

Chairs: Klaudia Palczak and Michael Evans-Brown, EMCDDA

Scottish Blues: The role of benzodiazepines in drug-related deaths in Scotland — Saket Priyadarshi, United Kingdom

Analyses of the special mortality register data (DRAMES) — Michel Mallaret, France

Brief national update and discussion based on special mortality registries:

- Update from the National Drug-Related Deaths Index — Ena Lynn, Ireland
- Update of Instituto Nacional de Medicina Legal e Ciências Forenses — Mario Dias, Portugal
- Update on BZD from Hjelt Institute, Department of Forensic Medicine — Ilkka Ojanperä, Finland

#### Mortality cohort studies among drug users (2B)

Chair: Marica Ferri, EMCDDA and Henrik Sælan, Denmark

Results of national mortality cohort study followed up to 2012 — Janusz Sieroslawski, Poland

A record-linkage study of opioid-related deaths and treatment for opioid misuse in England in 2008–11 — Martin White, United Kingdom

Cohort study in Central Asia (brief presentation) and database-linkage study among gamblers — Viktor Mravcik, Czech Republic

Assessing the gender effect in mortality risk and excess mortality from natural and external causes among heroin or cocaine users in Spain — Gregorio Barrio and Gemma Molist, Spain

Cardiovascular diseases as underlying cause of death among treated drug users — Jozica Selb, Slovenia

## Day 1 – Wednesday, 15 October 2014

12.30 Lunch (canteen)

13.45 **Session 3: DRD related to heroin and to methadone**

Chairs: John Strang, United Kingdom and Julian Vicente, EMCDDA

Deaths due to intravenous methadone use in Hamburg – using toxicological method to get information on the route of administration — Axel Heinemann, Germany

Poisoning deaths where methadone was implicated — Ena Lynn, Ireland

Overview of deaths among drug addicts with focus on methadone-related deaths — Tanja Coric, Croatia

Dramatic increase in DRD numbers compared to last year: heroin in cause? Review, analysis and implications — Bulent Sam, Turkey

Why have heroin-related deaths rebounded in England? An insight from the GMR (ONS, GROS, NISRA) and SMR (NPSAD and Scottish Drug Deaths Database) sources — John Corkery, United Kingdom

15.15 Coffee break

15.45 **Session 4: Cannabis-related emergencies and harm**

Chair: Roland Simon, EMCDDA

Key note speech on the adverse health effects of cannabis — Wayne Hall, Australia

European project Euro-DEN: Case-based analyses of acute emergencies related to cannabis in hospital emergency services in 10 countries — David Wood, United Kingdom

An update on cannabis: multi-indicator insight — Elena Alvarez, Spain

Review of some European national data on cannabis-related emergencies: strengths, limitations, public health implications — Marcis Trapencieris, Latvia

A drug treatment programme for young backpackers with psychosis due to cannabis abuse — Haim Mell, Israel

17.30 Cocktail

## Day 2 – Thursday, 16 October 2014

Conference Centre: **Joint DRD–DRID sessions**

09.30	<p><b>Session 5: High overdose mortality and HIV rates: multi-indicator insight on epidemiology and responses in Latvia and Estonia</b> Chairs: Dagmar Hedrich and Anda Karnite</p> <p>Drug overdose mortality in Estonia: toxicology, trends, role of fentanyl in drug-induced deaths — Gleb Denissov, Estonia</p> <p>Underestimation of overdose deaths in Latvia: an insight from coding of deaths in mortality cohort studies — Ildze Redoviča and Marcis Trapencieris, Latvia</p> <p>Improvements in the linkage between DRID and TDI in Latvia — Anda Karnite, Latvia</p> <p>Feedback from joint country mission on HIV and hepatitis B and C of ECDC and EMCDDA to Latvia in September 2014 — Nicole Werner Keiss, Latvia</p> <p>Short feedback from ECDC and EMCDDA</p> <p>Round table discussion</p>
11.00	Coffee break
11.30	<p><b>Session 6: Tackling HCV: morbidity, access to new treatments, treatment as prevention</b> Chairs: Isabelle Giraudon and Viktor Mravcik</p> <p>HCV treatment as prevention: evidence from work done in the UK and current EU funded project — Matthew Hickman, United Kingdom</p> <p>Update on HCV data and monitoring among PWID in Europe: evidence, limitations and way forward — Andrew Amato, ECDC</p> <p>Hepatitis Plus (Correlation) Access to HCV treatment: a European multisite study — Heike Zurhold, Germany</p> <p>An hepatologist perspective of HCV infection in Portugal — Rui Tato Marinho, Portugal</p> <p>Brief late breaking communications:</p> <ul style="list-style-type: none"> <li>• Multisite prevalence study 2014 among injectors and non injectors — Janusz Sieroslawski, Poland</li> <li>• Concerns with 2014 increasing HCV prevalence — Gergely Horvath, Hungary</li> </ul>
13.00	Lunch (Conference centre)
<b>DRID Key indicator meeting</b>	
14.00	<p><b>Session 7: Setting the scene / Introduction and update</b> Chair: Paul Griffiths</p> <p>Background, objectives and expected outcomes of the event — Paul Griffiths, EMCDDA</p> <p>Presentation/discussion of some recent reported national developments — Isabelle Giraudon, EMCDDA</p> <p>Injecting drug use and HIV, HBV and HCV. Preliminary results from the 'DRUCK-study' using respondent-driven sampling in cities with large drug scene in Germany — Ruth Zimmermann, RKI, Germany</p> <p>On-going projects / brief interventions:</p> <ul style="list-style-type: none"> <li>• Mephedrone injecting risks and infections in the United Kingdom — Vivian Hope, United Kingdom</li> <li>• Late breaking communications: Botulism outbreak — Hans Blystad, Norway</li> </ul>



## Day 3 – Friday, 17 October 2014

### Conference Centre

09.15	<p><b>Session 9: New threats, new injectors /NPS, new patterns of injecting: public health implications</b> Chairs: Vivian Hope and Isabelle Giraudon</p> <p>The use of crystal methamphetamine, GHB/GBL and mephedrone in sexual settings among gay men in London — Adam Bourne, United Kingdom</p> <p>Men who have sex with men and injecting drug use in Paris — Gregory Pfau, France</p> <p>Injection, infection, intoxications and fatalities: IDUs shifting completely from amphetamine/heroin to new psychoactive substances — Gergely Horvath, Hungary</p> <p>Injection NPS challenging for response in Poland — Artur Malczewski, Poland</p> <p>HIV outbreak related to injection of new psychoactive substances in Tel Aviv — Haim Mell, Israel</p>
11.00	Coffee break
11.30	<p><b>Session 10: Decreasing prevalence/changes of drug injecting and possible effects on service provision: panel discussion</b> Chairs: Roland Simon and Julian Vicente</p> <p>Estimating trends in injecting drug use in Europe using national data on drug treatment admissions and other data sets — Linda Montanari and Danica Thanki, EMCDDA</p> <p>Panel discussion with representatives from different sessions: Hans Blystad, Norway Xavier Majó i Roca, Spain Martin Busch, Austria Linda Montanari, EMCDDA Andrew Amato, ECDC Vivian Hope, United Kingdom</p>
13.00	Wrap-up and conclusions
13.15	End of the meeting